Improvement in Patient-reported Cognitive Functioning in Patients with Narcolepsy Type 1 Treated with the Orexin 2 Receptor Agonist Alixorexton (ALKS 2680)
Sleep Medicine, vol. 138, pp. 107525
Authors 13
-
Istituto delle Scienze Neurologiche di Bologna
Affiliation as printed
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
-
Inserm · Université de Montpellier · Institute for Neurosciences of Montpellier
Affiliation as printed
University of Montpellier, INSERM Institute for Neurosciences of Montpellier, Montpellier, France
-
Woolcock Institute of Medical Research · Macquarie University
Affiliation as printed
Woolcock Institute of Medical Research, Macquarie University, Sydney, Australia
-
Stanford Medicine · Stanford University
Affiliation as printed
Stanford University School of Medicine, Stanford Center for Narcolepsy and Hypersomnia, Stanford, United States
-
G.J. Lammers Aachen
Leiden University Medical Center · Stichting Epilepsie Instellingen Nederland
Affiliation as printed
Leiden University Medical Center and Stichting Epilepsie Instellingen Nederland Sleep-Wake Centre, Leiden, Netherlands
-
University of Wisconsin–Madison
Affiliation as printed
University of Wisconsin-Madison, School of Medicine and Public Health, Madison, United States
-
Affiliation as printed
ANIMA Research, Alken, Belgium
-
Affiliation as printed
Alkermes, Inc, Waltham, United States
-
Affiliation as printed
Alkermes, Inc, Waltham, United States
-
Affiliation as printed
Alkermes, Inc, Waltham, United States
-
Affiliation as printed
Alkermes, Inc, Waltham, United States
-
Affiliation as printed
Alkermes, Inc, Waltham, United States
Cited by 0 stored of 0
No patents citing this paper on Lens.org (checked 2026-10-11).